Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 233

1.

DOES SCREENING AND A RANDOMIZED BRIEF INTERVENTION AT A LEVEL 1 TRAUMA CENTER IMPACT ACUTE STRESS REACTIONS TO PREVENT LATER DEVELOPMENT OF POST TRAUMATIC STRESS DISORDER?

Manser SS, Houck K, Kramer MD, Tabas IA, Brown CVR, Coopwood B.

J Trauma Acute Care Surg. 2018 May 21. doi: 10.1097/TA.0000000000001977. [Epub ahead of print]

PMID:
29787532
2.

Hypercholesterolemia induces T cell expansion in humanized immune mice.

Proto JD, Doran AC, Subramanian M, Wang H, Zhang M, Sozen E, Rymond CC, Kuriakose G, D'Agati V, Winchester R, Sykes M, Yang YG, Tabas I.

J Clin Invest. 2018 Jun 1;128(6):2370-2375. doi: 10.1172/JCI97785. Epub 2018 Apr 30.

3.

Hepatocyte-secreted DPP4 in obesity promotes adipose inflammation and insulin resistance.

Ghorpade DS, Ozcan L, Zheng Z, Nicoloro SM, Shen Y, Chen E, Blüher M, Czech MP, Tabas I.

Nature. 2018 Mar 29;555(7698):673-677. doi: 10.1038/nature26138. Epub 2018 Mar 21.

4.

Circulation first - the time has come to question the sequencing of care in the ABCs of trauma; an American Association for the Surgery of Trauma multicenter trial.

Ferrada P, Callcut RA, Skarupa DJ, Duane TM, Garcia A, Inaba K, Khor D, Anto V, Sperry J, Turay D, Nygaard RM, Schreiber MA, Enniss T, McNutt M, Phelan H, Smith K, Moore FO, Tabas I, Dubose J; AAST Multi-Institutional Trials Committee.

World J Emerg Surg. 2018 Feb 5;13:8. doi: 10.1186/s13017-018-0168-3. eCollection 2018.

5.

Mechanisms and Consequences of Defective Efferocytosis in Atherosclerosis.

Yurdagul A Jr, Doran AC, Cai B, Fredman G, Tabas IA.

Front Cardiovasc Med. 2018 Jan 8;4:86. doi: 10.3389/fcvm.2017.00086. eCollection 2017. Review.

6.

Monocyte-Macrophages and T Cells in Atherosclerosis.

Tabas I, Lichtman AH.

Immunity. 2017 Oct 17;47(4):621-634. doi: 10.1016/j.immuni.2017.09.008. Review.

PMID:
29045897
7.

CAMKIIγ suppresses an efferocytosis pathway in macrophages and promotes atherosclerotic plaque necrosis.

Doran AC, Ozcan L, Cai B, Zheng Z, Fredman G, Rymond CC, Dorweiler B, Sluimer JC, Hsieh J, Kuriakose G, Tall AR, Tabas I.

J Clin Invest. 2017 Nov 1;127(11):4075-4089. doi: 10.1172/JCI94735. Epub 2017 Oct 3.

8.

Mitochondrial Fission Promotes the Continued Clearance of Apoptotic Cells by Macrophages.

Wang Y, Subramanian M, Yurdagul A Jr, Barbosa-Lorenzi VC, Cai B, de Juan-Sanz J, Ryan TA, Nomura M, Maxfield FR, Tabas I.

Cell. 2017 Oct 5;171(2):331-345.e22. doi: 10.1016/j.cell.2017.08.041. Epub 2017 Sep 21.

PMID:
28942921
9.

MerTK Cleavage on Resident Cardiac Macrophages Compromises Repair After Myocardial Ischemia Reperfusion Injury.

DeBerge M, Yeap XY, Dehn S, Zhang S, Grigoryeva L, Misener S, Procissi D, Zhou X, Lee DC, Muller WA, Luo X, Rothlin C, Tabas I, Thorp EB.

Circ Res. 2017 Sep 29;121(8):930-940. doi: 10.1161/CIRCRESAHA.117.311327. Epub 2017 Aug 29.

PMID:
28851810
10.

Mitochondrial Oxidative Stress Promotes Atherosclerosis and Neutrophil Extracellular Traps in Aged Mice.

Wang Y, Wang W, Wang N, Tall AR, Tabas I.

Arterioscler Thromb Vasc Biol. 2017 Aug;37(8):e99-e107. doi: 10.1161/ATVBAHA.117.309580. Epub 2017 Jun 8.

PMID:
28596373
11.

Boosting Inflammation Resolution in Atherosclerosis: The Next Frontier for Therapy.

Fredman G, Tabas I.

Am J Pathol. 2017 Jun;187(6):1211-1221. doi: 10.1016/j.ajpath.2017.01.018. Review.

12.

microRNA-33 Regulates Macrophage Autophagy in Atherosclerosis.

Ouimet M, Ediriweera H, Afonso MS, Ramkhelawon B, Singaravelu R, Liao X, Bandler RC, Rahman K, Fisher EA, Rayner KJ, Pezacki JP, Tabas I, Moore KJ.

Arterioscler Thromb Vasc Biol. 2017 Jun;37(6):1058-1067. doi: 10.1161/ATVBAHA.116.308916. Epub 2017 Apr 20.

13.

Hepatocyte TAZ/WWTR1 Promotes Inflammation and Fibrosis in Nonalcoholic Steatohepatitis.

Wang X, Zheng Z, Caviglia JM, Corey KE, Herfel TM, Cai B, Masia R, Chung RT, Lefkowitch JH, Schwabe RF, Tabas I.

Cell Metab. 2016 Dec 13;24(6):848-862. doi: 10.1016/j.cmet.2016.09.016. Epub 2016 Oct 27.

14.

MerTK receptor cleavage promotes plaque necrosis and defective resolution in atherosclerosis.

Cai B, Thorp EB, Doran AC, Sansbury BE, Daemen MJ, Dorweiler B, Spite M, Fredman G, Tabas I.

J Clin Invest. 2017 Feb 1;127(2):564-568. doi: 10.1172/JCI90520. Epub 2017 Jan 9.

15.

2016 Russell Ross Memorial Lecture in Vascular Biology: Molecular-Cellular Mechanisms in the Progression of Atherosclerosis.

Tabas I.

Arterioscler Thromb Vasc Biol. 2017 Feb;37(2):183-189. doi: 10.1161/ATVBAHA.116.308036. Epub 2016 Dec 15.

16.

Deficiency of AXL in Bone Marrow-Derived Cells Does Not Affect Advanced Atherosclerotic Lesion Progression.

Subramanian M, Proto JD, Matsushima GK, Tabas I.

Sci Rep. 2016 Dec 13;6:39111. doi: 10.1038/srep39111.

17.

Calcium signalling and ER stress in insulin resistance and atherosclerosis.

Ozcan L, Tabas I.

J Intern Med. 2016 Nov;280(5):457-464. doi: 10.1111/joim.12562. Epub 2016 Oct 14. Review.

18.

An imbalance between specialized pro-resolving lipid mediators and pro-inflammatory leukotrienes promotes instability of atherosclerotic plaques.

Fredman G, Hellmann J, Proto JD, Kuriakose G, Colas RA, Dorweiler B, Connolly ES, Solomon R, Jones DM, Heyer EJ, Spite M, Tabas I.

Nat Commun. 2016 Sep 23;7:12859. doi: 10.1038/ncomms12859.

19.

Heart disease: Death-defying plaque cells.

Tabas I.

Nature. 2016 Aug 4;536(7614):32-3. Epub 2016 Jul 20. No abstract available.

20.

Hepatocyte DACH1 Is Increased in Obesity via Nuclear Exclusion of HDAC4 and Promotes Hepatic Insulin Resistance.

Ozcan L, Ghorpade DS, Zheng Z, de Souza JC, Chen K, Bessler M, Bagloo M, Schrope B, Pestell R, Tabas I.

Cell Rep. 2016 Jun 7;15(10):2214-2225. doi: 10.1016/j.celrep.2016.05.006. Epub 2016 May 26.

21.

MerTK cleavage limits proresolving mediator biosynthesis and exacerbates tissue inflammation.

Cai B, Thorp EB, Doran AC, Subramanian M, Sansbury BE, Lin CS, Spite M, Fredman G, Tabas I.

Proc Natl Acad Sci U S A. 2016 Jun 7;113(23):6526-31. doi: 10.1073/pnas.1524292113. Epub 2016 May 19.

22.

Targeted Interleukin-10 Nanotherapeutics Developed with a Microfluidic Chip Enhance Resolution of Inflammation in Advanced Atherosclerosis.

Kamaly N, Fredman G, Fojas JJ, Subramanian M, Choi WI, Zepeda K, Vilos C, Yu M, Gadde S, Wu J, Milton J, Carvalho Leitao R, Rosa Fernandes L, Hasan M, Gao H, Nguyen V, Harris J, Tabas I, Farokhzad OC.

ACS Nano. 2016 May 24;10(5):5280-92. doi: 10.1021/acsnano.6b01114. Epub 2016 Apr 28.

23.

Macrophage Phenotype and Function in Different Stages of Atherosclerosis.

Tabas I, Bornfeldt KE.

Circ Res. 2016 Feb 19;118(4):653-67. doi: 10.1161/CIRCRESAHA.115.306256. Review.

24.

How an artery heals.

Williams KJ, Tabas I, Fisher EA.

Circ Res. 2015 Nov 6;117(11):909-13. doi: 10.1161/CIRCRESAHA.115.307609. No abstract available.

25.

Suppression of Adaptive Immune Cell Activation Does Not Alter Innate Immune Adipose Inflammation or Insulin Resistance in Obesity.

Subramanian M, Ozcan L, Ghorpade DS, Ferrante AW Jr, Tabas I.

PLoS One. 2015 Aug 28;10(8):e0135842. doi: 10.1371/journal.pone.0135842. eCollection 2015.

26.

Inflammation and plaque vulnerability.

Hansson GK, Libby P, Tabas I.

J Intern Med. 2015 Nov;278(5):483-93. doi: 10.1111/joim.12406. Epub 2015 Aug 11. Review.

27.

Treatment of Obese Insulin-Resistant Mice With an Allosteric MAPKAPK2/3 Inhibitor Lowers Blood Glucose and Improves Insulin Sensitivity.

Ozcan L, Xu X, Deng SX, Ghorpade DS, Thomas T, Cremers S, Hubbard B, Serrano-Wu MH, Gaestel M, Landry DW, Tabas I.

Diabetes. 2015 Oct;64(10):3396-405. doi: 10.2337/db14-1945. Epub 2015 Jun 11.

28.

C/EBP-Homologous Protein (CHOP) in Vascular Smooth Muscle Cells Regulates Their Proliferation in Aortic Explants and Atherosclerotic Lesions.

Zhou AX, Wang X, Lin CS, Han J, Yong J, Nadolski MJ, Borén J, Kaufman RJ, Tabas I.

Circ Res. 2015 May 22;116(11):1736-43. doi: 10.1161/CIRCRESAHA.116.305602. Epub 2015 Apr 14.

29.

Recent insights into the cellular biology of atherosclerosis.

Tabas I, García-Cardeña G, Owens GK.

J Cell Biol. 2015 Apr 13;209(1):13-22. doi: 10.1083/jcb.201412052. Review.

30.

Targeted nanoparticles containing the proresolving peptide Ac2-26 protect against advanced atherosclerosis in hypercholesterolemic mice.

Fredman G, Kamaly N, Spolitu S, Milton J, Ghorpade D, Chiasson R, Kuriakose G, Perretti M, Farokzhad O, Tabas I.

Sci Transl Med. 2015 Feb 18;7(275):275ra20. doi: 10.1126/scitranslmed.aaa1065. Erratum in: Sci Transl Med. 2015 Mar 4;7(277):277er2. Farokzhad, Omid [corrected to Farokhzad, Omid].

31.

Accelerating the pace of atherosclerosis research.

Daugherty A, Tabas I, Rader DJ.

Arterioscler Thromb Vasc Biol. 2015 Jan;35(1):11-2. doi: 10.1161/ATVBAHA.114.304833. No abstract available.

32.

Identification of a non-growth factor role for GM-CSF in advanced atherosclerosis: promotion of macrophage apoptosis and plaque necrosis through IL-23 signaling.

Subramanian M, Thorp E, Tabas I.

Circ Res. 2015 Jan 16;116(2):e13-24. doi: 10.1161/CIRCRESAHA.116.304794. Epub 2014 Oct 27.

33.

A solvent-free thermosponge nanoparticle platform for efficient delivery of labile proteins.

Choi WI, Kamaly N, Riol-Blanco L, Lee IH, Wu J, Swami A, Vilos C, Yameen B, Yu M, Shi J, Tabas I, von Andrian UH, Jon S, Farokhzad OC.

Nano Lett. 2014 Nov 12;14(11):6449-55. doi: 10.1021/nl502994y. Epub 2014 Oct 21.

34.

Resolvin D1 limits 5-lipoxygenase nuclear localization and leukotriene B4 synthesis by inhibiting a calcium-activated kinase pathway.

Fredman G, Ozcan L, Spolitu S, Hellmann J, Spite M, Backs J, Tabas I.

Proc Natl Acad Sci U S A. 2014 Oct 7;111(40):14530-5. doi: 10.1073/pnas.1410851111. Epub 2014 Sep 22.

35.

CaMKII in cardiometabolic disease.

Ozcan L, Tabas I.

Aging (Albany NY). 2014 Jun;6(6):430-1. No abstract available.

36.

Inflammation and its resolution as determinants of acute coronary syndromes.

Libby P, Tabas I, Fredman G, Fisher EA.

Circ Res. 2014 Jun 6;114(12):1867-79. doi: 10.1161/CIRCRESAHA.114.302699. Review.

37.

Common therapeutic targets in cardiometabolic disease.

Fredman G, Ozcan L, Tabas I.

Sci Transl Med. 2014 Jun 4;6(239):239ps5. doi: 10.1126/scitranslmed.3008908. Review.

38.

Emerging roles of mitochondria ROS in atherosclerotic lesions: causation or association?

Wang Y, Tabas I.

J Atheroscler Thromb. 2014;21(5):381-90. Epub 2014 Apr 8. Review.

39.

Interleukin-3/granulocyte macrophage colony-stimulating factor receptor promotes stem cell expansion, monocytosis, and atheroma macrophage burden in mice with hematopoietic ApoE deficiency.

Wang M, Subramanian M, Abramowicz S, Murphy AJ, Gonen A, Witztum J, Welch C, Tabas I, Westerterp M, Tall AR.

Arterioscler Thromb Vasc Biol. 2014 May;34(5):976-84. doi: 10.1161/ATVBAHA.113.303097. Epub 2014 Mar 20.

40.

A new RIDDle in DC-mediated cross-presentation.

Subramanian M, Tabas I.

Nat Immunol. 2014 Mar;15(3):213-5. doi: 10.1038/ni.2826. No abstract available.

41.

An AXL/LRP-1/RANBP9 complex mediates DC efferocytosis and antigen cross-presentation in vivo.

Subramanian M, Hayes CD, Thome JJ, Thorp E, Matsushima GK, Herz J, Farber DL, Liu K, Lakshmana M, Tabas I.

J Clin Invest. 2014 Mar;124(3):1296-308. doi: 10.1172/JCI72051. Epub 2014 Feb 10.

42.

Macrophage mitochondrial oxidative stress promotes atherosclerosis and nuclear factor-κB-mediated inflammation in macrophages.

Wang Y, Wang GZ, Rabinovitch PS, Tabas I.

Circ Res. 2014 Jan 31;114(3):421-33. doi: 10.1161/CIRCRESAHA.114.302153. Epub 2013 Dec 2.

43.

Activation of calcium/calmodulin-dependent protein kinase II in obesity mediates suppression of hepatic insulin signaling.

Ozcan L, Cristina de Souza J, Harari AA, Backs J, Olson EN, Tabas I.

Cell Metab. 2013 Dec 3;18(6):803-15. doi: 10.1016/j.cmet.2013.10.011. Epub 2013 Nov 21.

44.

Dendritic cells in atherosclerosis.

Subramanian M, Tabas I.

Semin Immunopathol. 2014 Jan;36(1):93-102. doi: 10.1007/s00281-013-0400-x. Epub 2013 Nov 6. Review.

45.

Cross-section Trichometry: A Clinical Tool for Assessing the Progression and Treatment Response of Alopecia.

Wikramanayake TC, Mauro LM, Tabas IA, Chen AL, Llanes IC, Jimenez JJ.

Int J Trichology. 2012 Oct;4(4):259-64. doi: 10.4103/0974-7753.111221.

46.

Making things stick in the fight against atherosclerosis.

Tabas I.

Circ Res. 2013 Apr 12;112(8):1094-6. doi: 10.1161/CIRCRESAHA.113.301227. No abstract available.

47.

The UPR in atherosclerosis.

Zhou AX, Tabas I.

Semin Immunopathol. 2013 May;35(3):321-32. doi: 10.1007/s00281-013-0372-x. Epub 2013 Apr 4. Review.

48.

Development and in vivo efficacy of targeted polymeric inflammation-resolving nanoparticles.

Kamaly N, Fredman G, Subramanian M, Gadde S, Pesic A, Cheung L, Fayad ZA, Langer R, Tabas I, Farokhzad OC.

Proc Natl Acad Sci U S A. 2013 Apr 16;110(16):6506-11. doi: 10.1073/pnas.1303377110. Epub 2013 Mar 26.

49.

Anti-inflammatory therapy in chronic disease: challenges and opportunities.

Tabas I, Glass CK.

Science. 2013 Jan 11;339(6116):166-72. doi: 10.1126/science.1230720. Review.

50.

Treg-mediated suppression of atherosclerosis requires MYD88 signaling in DCs.

Subramanian M, Thorp E, Hansson GK, Tabas I.

J Clin Invest. 2013 Jan;123(1):179-88. doi: 10.1172/JCI64617. Epub 2012 Dec 21.

Supplemental Content

Support Center